Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Highlights from ESMO 2021: mucosal and acral melanoma

Ines Pires Da Silva • 28 Sep 2021
ESMO 2021
Melanoma Skin Cancer

Ines Pires da Silva, MD, PhD, Melanoma Institute Australia and The University of Sydney, Sydney, Australia, outlines two large studies on mucosal and acral melanoma that were presented at ESMO 2021. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr da Silva reports travel support by BMS and MSD, and speaker fee by Roche, BMS, MSD and Novartis.

More from Ines Pires Da Silva

9:24
Anti-PD1 monotherapy or combination with ipi after BRAF/MEK inhibitors in BRAF-mutant melanoma
Ines Pires Da Silva • 28 Sep 2021
3:39
KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanoma
Ines Pires Da Silva • 28 Sep 2021
7:13
Progression patterns in post-ipilimumab and anti-PD-1 in metastatic melanoma
Ines Pires Da Silva • 31 May 2021

Related Videos

1:20
Can ctDNA guide the treatment decision making process in melanoma?
Christoffer Gebhardt • 9 Apr 2024
1:18
Elucidating ICI resistance in melanoma with ctDNA and tumor profiling
Christoffer Gebhardt • 9 Apr 2024
1:48
Ultra-sensitive ctDNA monitoring predicts ICI response in melanoma
Christoffer Gebhardt • 9 Apr 2024
1:56
Challenges and opportunities in TILs and TCR modified cell therapies
Sebastian Klobuch • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals